Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915114 | 1.00 | KMT2A (0.43) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL915449 | 0.89 | KMT2A (0.52) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL915448 | 0.89 | KMT2A (0.52) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL916217 | 0.88 | KMT2A (0.44) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL916218 | 0.88 | KMT2A (0.44) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL915110 | 0.78 | KMT2A (0.37) | KMT2ALMNA | |
| SCHEMBL915115 | 0.78 | KMT2A (0.37) | KMT2ALMNA | |
| SCHEMBL925792 | 0.76 | KMT2A (0.54) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| SCHEMBL925790 | 0.76 | KMT2A (0.54) | KMT2ASMN1; SMN2LMNAPLGPLAT | |
| Bicarbonate SCHEMBL3255652 | 0.75 | CTSK (0.40) | KMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885LMNA 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.